A high-throughput fluorescence polarization assay for inhibitors of gyrase B

Journal of Biomolecular Screening

Volumn 16, Issue 2, 2011, Pages 230-238

  Glaser, Bryan T ^a   Malerich, Jeremiah P ^a   Duellman, Sarah J ^a   Fong, Julie ^a   Hutson, Christopher ^a   Fine, Richard M ^b   Keblansky, Boris ^b   Tanga, Mary J ^a   Madrid, Peter B ^a  

^a SRI INTERNATIONAL   (United States)

^b BioPredict   (United States)

Author keywords

anthracycline; assay development; fluorescence polarization; gyrase; high throughput screen

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOXORUBICIN; EPIRUBICIN; HOLOENZYME; IDARUBICIN; ISOMERASE INHIBITOR; N ETHYL N' [7 (2 PYRIDINYL) 5 (3 PYRIDINYL) 1H BENZIMIDAZOL 2 YL]UREA; NOVOBIOCIN; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VERTEX 13;

ARTICLE; BACTERIAL VIABILITY; BINDING KINETICS; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ESCHERICHIA COLI; FLUORESCENCE POLARIZATION; FRANCISELLA TULARENSIS; HIGH THROUGHPUT SCREENING; IC 50; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; STAPHYLOCOCCUS AUREUS;

ADENOSINE TRIPHOSPHATE; BINDING SITES; DNA GYRASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; FLUORESCENCE POLARIZATION; HIGH-THROUGHPUT SCREENING ASSAYS; KINETICS; MOLECULAR DYNAMICS SIMULATION; NOVOBIOCIN; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SMALL MOLECULE LIBRARIES;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS;

EID: 79951996244     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110392038     Document Type: Article

References (28)

1. Nollmann M., Crisona NJ, Arimondo PB: Thirty years of Escherichia coli DNA gyrase: from in vivo function to single-molecule mechanism. Biochimie 2007 ; 89: 490-499. (Pubitemid 46634704)
2. Berger JM, Wang JC: Recent developments in DNA topoisomerase II structure and mechanism. Curr Opin Struct Biol 1996 ; 6: 84-90. (Pubitemid 26073948)
3. Schoeffler AJ, Berger JM: Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans 2005 ; 33: 1465-1470. (Pubitemid 41779716)
4. Sugino A., Higgins NP, Brown PO, Peebles CL, Cozzarelli NR: Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci U S A 1978 ; 75: 4838-4842. (Pubitemid 9048630)
5. Marko O., Miha K., Tom S.: Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 2007 ; 14: 2033-2047.
6. Nakada N., Gmünder H., Hirata T., Arisawa M.: Characterization of the binding site for cyclothialidine on the B subunit of DNA gyrase. J Biol Chem 1995 ; 270: 14286-14291.
7. Hooper DC, Wolfson JS, Ng EY, Swartz MN: Mechanisms of action of and resistance to ciprofloxacin. Am J Med 1987 ; 82: 12-20.
8. Smith JT: The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 1986 ; 18 (suppl D). 21-29. (Pubitemid 17214190)
9. Gross CH, Parsons JD, Grossman TH, Charifson PS, Bellon S., Jernee J.,, et al. Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance. Antimicrob Agents Chemother 2003 ; 47: 1037-1046. (Pubitemid 36254232)
10. Boehm HJ, Boehringer M., Bur D., Gmuender H., Huber W., Klaus W.,, et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000 ; 43: 2664-2674. (Pubitemid 30463915)
11. Reece RJ, Maxwell A.: Tryptic fragments of the Escherichia coli DNA gyrase A protein. J Biol Chem 1989 ; 264: 19648-19653. (Pubitemid 20008070)
12. Roychoudhury S., Makin KM, Twinem TL, Stanton DT, Nelson SL, Catrenich CE: Development and use of a high-throughput bacterial DNA gyrase assay to identify mammalian topoisomerase II inhibitors with whole-cell anticancer activity. J Biomol Screen 2003 ; 8: 157-163.
13. Burrell MR, Burton NP, Maxwell A.: A high-throughput assay for DNA topoisomerases and other enzymes, based on DNA triplex formation. Methods Mol Biol 2010 ; 613: 257-266.
14. Moir DT, Ming D., Opperman T., Schweizer HP, Bowlin TL: A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agents. J Biomol Screen 2007 ; 12: 855-864. (Pubitemid 47340706)
15. Gevi M., Domenici E.: A scintillation proximity assay amenable for screening and characterization of DNA gyrase B subunit inhibitors. Anal Biochem 2002 ; 300: 34-39. (Pubitemid 34066802)
16. Owicki JC: Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen 2000 ; 5: 297-306.
17. Roehrl MH, Wang JY, Wagner G.: A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization. Biochemistry 2004 ; 43: 16056-16066. (Pubitemid 40041019)
18. Lamour V., Hoermann L., Jeltsch JM, Oudet P., Moras D.: An open conformation of the Thermus thermophilus gyrase B ATP-binding domain. J Biol Chem 2002 ; 277: 18947-18953. (Pubitemid 34952456)
19. Larsson P., Oyston PC, Chain P., Chu MC, Duffield M., Fuxelius HH,, et al. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet 2005 ; 37: 153-159.
20. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73. (Pubitemid 29278954)
21. Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M., Bellon S.,, et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 2008 ; 51: 5243-5263.
22. Holdgate GA, Tunnicliffe A., Ward WH, Weston SA, Rosenbrock G., Barth PT,, et al. The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study. Biochemistry 1997 ; 36: 9663-9673. (Pubitemid 27364677)
23. Gabbay EJ, Grier D., Fingerle RE, Reimer R., Levy R., Pearce SW,, et al. Interaction specificity of the anthracyclines with deoxyribonucleic acid. Biochemistry 1976 ; 15: 2062-2070.
24. Khan F., Sherwani AF, Afzal M.: Chromosomal aberration and micronucleus studies of two topoisomerase (II) targeting anthracyclines. J Environ Biol 2009 ; 30: 409-412.
25. Saffi J., Agnoletto MH, Guecheva TN, Batista LF, Carvalho H., Henriques JA,, et al. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells. DNA Repair (Amst) 2010 ; 9: 40-47.
26. Bodley A., Liu LF, Israel M., Seshadri R., Koseki Y., Giuliani FC,, et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989 ; 49: 5969-5978. (Pubitemid 19274156)
27. Viglasky V., Valle F., Adamcik J., Joab I., Podhradsky D., Dietler G.: Anthracycline-dependent heat-induced transition from positive to negative supercoiled DNA. Electrophoresis 2003 ; 24: 1703-1711. (Pubitemid 38088956)
28. Waring M.: Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: evidence for molecular models involving intercalation. J Mol Biol 1970 ; 54: 247-279.